ACA
GYRE icon

Apis Capital Advisors’s Gyre Therapeutics GYRE Stock Holding History

Apis Capital Advisors’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-13
Closed -$28K – 45
2015
Q2 		$28K Buy
+13
New +$26.1K 0.03% 43

Other funds holding GYRE

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Apis Capital Advisors's GYRE Position: Q3 2015 in Review

Apis Capital Advisors sold out of Gyre Therapeutics (GYRE) in Q3 2015, closing a stake of 13 shares — an estimated $28K sold.

Apis Capital Advisors first reported a position in GYRE in Q2 2015 and held it in 1 quarter. The position peaked at $28K in Q2 2015. 39 funds tracked by Wall St. Rank hold GYRE as of Q3 2015.

  • Apis Capital Advisors reported no remaining Gyre Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Apis Capital Advisors sold 13 Gyre Therapeutics shares in Q3 2015, an estimated $28K.
  • Apis Capital Advisors first reported a position in Gyre Therapeutics in Q2 2015 and held it in 1 quarter.
  • Apis Capital Advisors's Gyre Therapeutics position peaked at $28K in Q2 2015.
  • 39 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2015.

Based on Apis Capital Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.